153 related articles for article (PubMed ID: 33961922)
1. Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use.
Amigo M; Hoffman K; Chung C; Lustberg M; Wesolowski R; VanDeusen J; Stover D; Suarez GT; Cherian M; Kaffenberger B; Dulmage B
J Am Acad Dermatol; 2022 Jun; 86(6):1346-1348. PubMed ID: 33961922
[No Abstract] [Full Text] [Related]
2. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
[TBL] [Abstract][Full Text] [Related]
4. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.
Thullberg M; Bartkova J; Khan S; Hansen K; Rönnstrand L; Lukas J; Strauss M; Bartek J
FEBS Lett; 2000 Mar; 470(2):161-6. PubMed ID: 10734227
[TBL] [Abstract][Full Text] [Related]
5. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.
Koduru PR; Zariwala M; Soni M; Gong JZ; Xiong Y; Broome JD
Blood; 1995 Oct; 86(8):2900-5. PubMed ID: 7579381
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
[TBL] [Abstract][Full Text] [Related]
7. Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.
Fink JR; LeBien TW
Exp Hematol; 2001 Apr; 29(4):490-8. PubMed ID: 11301189
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
Phelps DE; Xiong Y
Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood.
Takeuchi S; Bartram CR; Seriu T; Miller CW; Tobler A; Janssen JW; Reiter A; Ludwig WD; Zimmermann M; Schwaller J
Blood; 1995 Jul; 86(2):755-60. PubMed ID: 7606004
[TBL] [Abstract][Full Text] [Related]
10. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
Calbó J; Serna C; Garriga J; Graña X; Mazo A
Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
Parry D; Mahony D; Wills K; Lees E
Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
[TBL] [Abstract][Full Text] [Related]
12. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development.
Chellappan SP; Giordano A; Fisher PB
Curr Top Microbiol Immunol; 1998; 227():57-103. PubMed ID: 9479826
[No Abstract] [Full Text] [Related]
13. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle inhibitors (p27Kip1 and p21CIP1) cause hypertrophy in LLC-PK1 cells.
Terada Y; Inoshita S; Nakashima O; Tamamori M; Ito H; Kuwahara M; Sasaki S; Marumo F
Kidney Int; 1999 Aug; 56(2):494-501. PubMed ID: 10432388
[TBL] [Abstract][Full Text] [Related]
15. The INK4 family of CDK inhibitors.
Carnero A; Hannon GJ
Curr Top Microbiol Immunol; 1998; 227():43-55. PubMed ID: 9479825
[No Abstract] [Full Text] [Related]
16. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
17. Severe drug eruption induced by cyclin-dependent kinase 4 and 6 inhibitor.
Hashimoto H; Ito T; Ohno F; Morisawa H; Furue M
J Dermatol; 2021 Jul; 48(7):e339-e340. PubMed ID: 33878226
[No Abstract] [Full Text] [Related]
18. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.
Schreiber M; Muller WJ; Singh G; Graham FL
Oncogene; 1999 Mar; 18(9):1663-76. PubMed ID: 10208428
[TBL] [Abstract][Full Text] [Related]
19. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Akagi M; Tahara H; Ishikawa T; Tahara E
Jpn J Cancer Res; 1996 Aug; 87(8):824-30. PubMed ID: 8797888
[TBL] [Abstract][Full Text] [Related]
20. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
